Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13505458 | 0.84 | NAMPT (0.48) | NAMPTHTR2CHRH4HRH3AKT1 | |
| SCHEMBL1994788 | 0.84 | NAMPT (0.38) | NAMPTHTR2CHRH4HRH3AKT1 | |
| SCHEMBL28625656 | 0.84 | NAMPT (0.37) | NAMPTHTR2CMMP8MMP3AKT1 | |
| SCHEMBL29959822 | 0.80 | NAMPT (0.35) | NAMPTHTR2CHRH4HRH3MMP8 | |
| SCHEMBL31214426 | 0.77 | SRC (0.35) | SCN9AKDM4EALDH1A1 | |
| SCHEMBL17373227 | 0.76 | NR1H2 (0.40) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24229770 | 0.73 | NAMPT (0.47) | NAMPTHTR2CHRH4HRH3AKT1 | |
| SCHEMBL22915890 | 0.71 | KDM4E (0.47) | NAMPTHTR2CKDM4E | |
| SCHEMBL20214421 | 0.71 | NAMPT (0.56) | NAMPTHTR2CENPP2KDM4E | |
| Trifluoroacetic Acid SCHEMBL31214326 | 0.71 | SCN9A (0.36) | HRH4HRH3SCN9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4357347-B1 | TRK KINASE INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-12-11 | — | — | EP | claimed |
| EP-3932919-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-06-26 | — | — | EP | claimed |
| EP-4357347-A1 | TRK KINASE INHIBITOR COMPOUND AND USE THEREOF | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4556477-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556478-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119591604-A | JAK inhibitor compounds and uses thereof | 迈英诺医药科技（珠海）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025036296-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | 迈英诺医药科技（珠海）有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2022268080-A1 | TRK KINASE INHIBITOR COMPOUND AND USE THEREOF | 河南迈英诺医药科技有限公司 | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | TGFB1, TGFB2, TGFBR1 | NAMPT 644/4885HTR2C 4683/4885HRH4 1565/4885 |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | TGFB1, TGFB2, TGFBR2 | NAMPT 369/4885HTR2C 4304/4885HRH4 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.